Vimarsana
Biggest News Aggregation in the World

Page 18 - Consultancy Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Consultancy Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Consultancy Services Today - Breaking & Trending Today

Wipro ends a dismal year, and the next quarter may be no better either - Vimarsana News

Wipro ends a dismal year, and the next quarter may be no better either

Wipro Q4 Results: Net profit drops 8% to ₹2,835 crore, revenue down 4% YoY

TCS outperforms Infosys in revenue growth for the first time in five years - Vimarsana News

TCS outperforms Infosys in revenue growth for the first time in five years

Although TCS is much bigger than Infosys in size, it has still outperformed its Bengaluru-based next-best rival hands down.

Markets recover sharply to close higher, but still end down for the weak amid FII selling - Vimarsana News

Markets recover sharply to close higher, but still end down for the weak amid FII selling

Sensex ended 599 points or 0.8 per cent higher at 73,088.33 level

Source: theweek.in
TCS Vs Infosys Vs Wipro Q4 Results: Who Performed Better And Why? - Vimarsana News

TCS Vs Infosys Vs Wipro Q4 Results: Who Performed Better And Why?

TCS outperforms its peers in Q4 financial results; analysts say financials for Infosys and Wipro were weak as the companies were not able to ensure timely ramp-up of deals

Source: news18.com
Iran-Israel conflict: India Inc closely watches developments to ensure safety of employees in West Asia - Vimarsana News

Iran-Israel conflict: India Inc closely watches developments to ensure safety of employees in West Asia

Sun Pharma, which operates in Israel through its subsidiary Taro Pharmaceutical, is actively monitoring the situation in the country and is taking all necessary steps to ensure safety and wellbeing of employees and their families, a company spokesperson said in an email response to ET.